Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 9, 2016, Pages 957-966

  Marcellin, P ^a   Ahn, S H ^a   Chuang, W L ^a   Hui, A J ^a   Tabak, F ^a   Mehta, R ^a   Petersen, J ^a   Lee, C M ^a   Ma, X ^a   Caruntu, F A ^a   Tak, W Y ^a   Elkhashab, M ^a   Lin, L ^b   Wu, G ^b   Martins, E B ^b   Charuworn, P ^b   Yee, L J ^b   Lim, S G ^a   Foster, G R ^c   Fung, S ^a   Morano, L ^a   Samuel, D ^a   Agarwal, K ^c   Idilman, R ^a   Strasser, S I ^a   Buti, M ^a   Gaeta, G B ^a   Papatheodoridis, G ^a   Flisiak, R ^a   Chan, H L Y ^a   more..

^a Gilead Sciences Inc ^*  (Poland)

^b GILEAD SCIENCES   (United States)

^c London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; TENOFOVIR DISOPROXIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SELECTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SECONDARY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84991099430     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13779     Document Type: Article

References (26)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis B virus infection. J Hepatol 2012; 57: 167–85.
2. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531–61.
3. Terrault N, Bzowej N, Chang K-H, Jonas MM, Murad MM. AASLD guidelines for treatment of hepatitis B. Hepatology 2015; 63: 261–83.
4. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–17.
5. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–95.
6. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442–55.
7. Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016; 150: 134–44.
8. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699–705.
9. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5- year open-label follow-up study. Lancet 2013; 381: 468–75.
10. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32–5.
11. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of pro-longed treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 238–43.
12. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301.
13. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091–7.
14. Takkenberg RB, Jansen L, de Niet A, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antivir Ther 2013; 18: 895–904.
15. Brouwer WP, Sonneveld MJ, Xie Q, et al. Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2015; 23: 419–26.
16. Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015; 42: 243–57.
17. Afyon M. Letter: nucleos(t)ide analogues are good, but not sufficient for hepatitis B virus clearance. Aliment Pharmacol Ther 2016; 43: 654–5.
18. Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014; 40: 804–10.
19. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151–7.
20. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454–61.
21. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006–11.
22. Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7: 88–97.
23. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323–5.
24. Piratvisuth T, Marcellin P, Popescu M, Kapprell H-P, Rothe V, Lu Z-M. Hepatitis B surface antigen: association with sustained response to pegylated interferon alfa-2a in hepatitis B e antigen positive patients. Hepatol Int 2013; 7: 429–36.
25. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251–7.
26. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872–80.